Introduction

  • Empiric anti-MRSA therapy (vancomycin or linezolid) is often started for pneumonia when local MRSA rates are high, MRSA risk factors are present, or the pathogen is unknown (2016 IDSA/ATS guideline). Starting it is reasonable. The hard part is knowing when to stop.
  • The MRSA nasal swab (a PCR of the nares) is a fast test many patients already have. A negative result has a high negative predictive value (NPV) for MRSA pneumonia and supports stopping empiric anti-MRSA coverage.
  • It rules out, not in. A negative swab makes MRSA pneumonia unlikely. A positive swab is right only about 45% of the time (PPV 44.8% at 10% prevalence), so a positive result alone should not keep coverage going.
  • The numbers depend on prevalence (the 96.5% NPV assumes about 10% MRSA-pneumonia prevalence). The test is strongest in community and healthcare-associated pneumonia (CAP/HCAP) and weakest in ventilator-associated pneumonia (VAP), where sensitivity is only about 40%.
  • Stopping coverage you no longer need cuts drug exposure, vancomycin level draws, and resistance pressure. Those are the stewardship wins.
  • This is evidence-supported stewardship, not a formal guideline recommendation. No current pneumonia guideline endorses swab-guided de-escalation. Always use your local antibiogram and protocol.

Clinical Detail

How the swab performs

Pooled diagnostic performance for ruling out MRSA pneumonia (Parente 2018, 22 studies, 5,163 patients).

All MRSA pneumonia
(~10% prevalence)		CAP / HCAPVAP
Negative predictive value (NPV)96.5%98.1%94.8%
Positive predictive value (PPV)44.8%56.8%35.7%
Sensitivity70.9%85.0%40.3%
Specificity90.3%92.1%93.7%

Turnaround: The swab (PCR) comes back much faster than a respiratory culture, which usually takes about 48 to 72 hours. Exact PCR turnaround depends on your lab, so confirm it locally.

Collection window: Collect the swab within about 7 days of the culture or infection onset for de-escalation (Smith 2019; NPV 76 to 99.4% across pneumonia types).

Bottom line: A negative swab strongly supports stopping coverage in CAP/HCAP. A positive swab is not proof of MRSA pneumonia (PPV about 45%). Be more careful in VAP (sensitivity about 40%). The numbers shift with prevalence, so apply your local MRSA rate and antibiogram.
Framing: This is evidence-supported antimicrobial stewardship, not a formal guideline recommendation. No current pneumonia guideline endorses nasal-swab-guided de-escalation.

Predictive values are prevalence-dependent; always interpret alongside cultures, clinical course, and your institution's protocol.

Evidence

StudyDesign / NIntervention & comparisonOutcome
Dangerfield B, et al., 2014Retrospective cohort; n=435 (55% HCAP, 34% CAP)Nasal MRSA PCR vs respiratory culture for confirmed MRSA pneumoniaSensitivity 88.0%, specificity 90.1%, PPV 35.4%, NPV 99.2% (MRSA-pneumonia rate 5.7%). Landmark first cohort; a negative PCR can reasonably guide de-escalation.
Smith MN, et al., 2017Retrospective ICU cohort; n=400 nosocomial pneumoniaNasal MRSA PCR vs respiratory culture in critically ill patientsSensitivity 91.9%, specificity 84.3%, PPV 37.4%, NPV 99.0% (rate 9.3%). NPV fell to 87.5% by about 22 days. About $108 per patient in vancomycin and monitoring costs avoided.
Parente DM, et al., 2018Diagnostic meta-analysis; 22 studies, 5,163 patientsPooled nasal MRSA swab vs respiratory culturePooled NPV 96.5% (all types), 98.1% CAP/HCAP, 94.8% VAP. PPV only 44.8%. Sensitivity 70.9%, specificity 90.3% (VAP sensitivity 40.3%). The pooled anchor for the rule-out logic.
Lewis AD, et al., 2022Retrospective; n=161 (VAP, lung abscess, empyema)Nasal MRSA PCR vs respiratory culture in lower-respiratory infectionsVAP: sensitivity 100%, NPV 100% (PPV 67%). Empyema NPV 97%. Adds primary VAP data supporting cautious use of the swab in VAP.
Baby N, Faust AC, et al., 2017Retrospective pre/post; n=57 (27 pre / 30 post)Pharmacist-driven nasal MRSA PCR to guide stopping empiric vancomycin/linezolidAnti-MRSA therapy shortened by 46.6 h (95% CI 27.3 to 65.8; P<0.0001). Fewer vancomycin levels. No difference in length of stay or mortality.
Marinucci V, et al., 2023Single-center pre/post, 4 ICUs; n=100 (50 vs 50 matched)Pharmacist-driven MRSA-PCR algorithm vs standard careAnti-MRSA therapy fell from 95 h to 47 h (P<0.001). Fewer vancomycin levels (3 vs 2, P=0.026). No difference in MRSA rates, length of stay, or mortality.
Sindelar MA, et al., 2022Single-center cohort; n=341 (ED-admitted pneumonia)Negative ED-collected MRSA PCR vs no ED swab; early stop (1 dose or less)Only 35.2% of negative-swab patients got more than 1 dose of an MRSA-active agent vs 52% with no swab (P<0.01). No difference in AKI, length of stay, or mortality. Pushes the stop upstream to the ED.
Freiberg JA, et al. (STOP-Vanc), 2026Pragmatic single-center RCT; n=277 ICU, suspected CAPUsual care with or without MRSA nares PCR plus a prompt to stop vancomycinNasal PCR NPV 98.9%, but vancomycin-free hours alive did not differ (105.7 vs 109.7; adjusted +4 h; 95% CI -9.5 to 18.2; P=0.46). No mortality difference. A high NPV alone did not change prescribing without added stewardship. The only RCT, and the honest counterpoint.
Kalil AC, et al., 2016IDSA/ATS HAP/VAP clinical practice guidelineWhen to start empiric MRSA coverage (vancomycin or linezolid)Bases empiric MRSA therapy on risk factors (prior IV antibiotics, septic shock, high or unknown local MRSA rate). Does not address nasal-swab de-escalation.

Also cited: Smith MN, et al., 2019 systematic review (19 studies, 21,790 patients; NPV 76 to 99.4%) for the ~7-day collection window. Diagnostic accuracy is consistent across cohorts; the one RCT (STOP-Vanc) shows a high NPV does not reduce vancomycin use on its own without an active prompt to stop.

Conclusions

  • A negative MRSA nasal swab has a high NPV (about 96.5% at 10% prevalence, about 98% in CAP/HCAP). It strongly supports stopping empiric anti-MRSA therapy, most of all in community and healthcare-associated pneumonia.
  • Rule out, not rule in. A positive swab is right only about 45% of the time and should not, by itself, keep anti-MRSA coverage going.
  • Be more careful in VAP, where sensitivity drops to about 40% (NPV still 94.8%). Pair the swab with clinical judgment and cultures.
  • Acting on a negative swab cut anti-MRSA therapy by about 2 days (Baby 2017; Marinucci 2023, from 95 h to 47 h) with no rise in death or length of stay, and it can happen as early as the emergency department (Sindelar 2022).
  • A high NPV does not change prescribing on its own. In the only randomized trial (STOP-Vanc, 2026), adding the swab did not cut vancomycin days without a prompt to stop. Pair a negative result with an active recommendation to de-escalate.
  • The numbers depend on prevalence, and the swab should be collected within about 7 days of the culture or infection. Apply your local MRSA rate and antibiogram.
  • This is evidence-supported stewardship, not a formal guideline recommendation. The 2016 IDSA/ATS guideline bases empiric MRSA therapy on risk factors and does not address swab-guided de-escalation. Individualize and follow your protocol.

References

  • Dangerfield B, Chung A, Webb B, Seville MT. Predictive value of MRSA nasal swab PCR assay for MRSA pneumonia. Antimicrob Agents Chemother. 2014;58(2):859-864. doi:10.1128/AAC.01805-13 PubMed
  • Smith MN, Erdman MJ, Ferreira JA, Aldridge P, Jankowski CA. Clinical utility of MRSA nasal PCR assay in critically ill patients with nosocomial pneumonia. J Crit Care. 2017;38:168-171. doi:10.1016/j.jcrc.2016.11.008 PubMed
  • Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The clinical utility of MRSA nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1-7. doi:10.1093/cid/ciy024 PubMed
  • Lewis AD, Bridwell MR, Hambuchen MD, Clay TB, Orwig KW. Correlation of MRSA PCR nasal swab in ventilator-associated pneumonia, lung abscess, and empyema. Diagn Microbiol Infect Dis. 2022;105(1):115836. doi:10.1016/j.diagmicrobio.2022.115836 PubMed
  • Baby N, Faust AC, Smith T, Sheperd LA, Knoll L, Goodman EL. Nasal MRSA PCR testing reduces the duration of MRSA-targeted therapy in patients with suspected MRSA pneumonia. Antimicrob Agents Chemother. 2017;61(4):e02432-16. doi:10.1128/AAC.02432-16 PubMed
  • Marinucci V, Louzon PR, Carr AL, Hayes J, Lopez-Ruiz A, Sniffen J. Pharmacist-driven MRSA PCR testing for pneumonia. Ann Pharmacother. 2023;57(5):560-569. doi:10.1177/10600280221121144 PubMed
  • Sindelar MA, Zepeski AE, Lawler BJ, Johnston SD, Faine BA. MRSA nasal swab PCR to de-escalate antibiotics in the emergency department. Am J Emerg Med. 2022;55:133-137. doi:10.1016/j.ajem.2022.03.009 PubMed
  • Freiberg JA, Qian ET, Nairon KG, et al. Swab testing to optimize pneumonia treatment with empiric vancomycin (STOP-Vanc): a randomized controlled trial. Clin Infect Dis. 2026. doi:10.1093/cid/ciag295 PubMed
  • Smith MN, Brotherton AL, Lusardi K, Tan CA, Hammond DA. Systematic review of the clinical utility of MRSA nasal screening for MRSA pneumonia. Ann Pharmacother. 2019;53(6):627-638. doi:10.1177/1060028018823027 PubMed
  • Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the IDSA and ATS. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353 PubMed
  • Micromedex [Electronic version]. Greenwood Village, CO: Truven Health Analytics. Retrieved July 2026, from http://www.micromedexsolutions.com/
Tags:MRSAnasal swabpneumoniaantimicrobial stewardshipde-escalationvancomycin